期刊
CURRENT PHARMACEUTICAL DESIGN
卷 17, 期 15, 页码 1483-1499出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161211796197124
关键词
Ubiquitin-proteasome system; bortezomib; mechanism of action
资金
- Czech Science Foundation [303/08/P137, 304/10/0149]
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib(Velcade (R)) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. There have been almost 200 clinical trials with bortezomib, both as a single agent and in combination with other drugs, for various cancers, as listed in the US National Cancer Institute database. However, bortezomib's mechanism of action remains elusive despite enormous progress in our knowledge of the cell biology of the ubiquitin-proteasome system (UPS) and bortezomib-induced signaling events in cancer cells. This review maps a rapidly growing and open body of research in both areas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据